Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer

Haas, Maximilian and Mayr, Roman and Sikic, Danijel and Wullich, Bernd and Kluemper, Niklas and Erben, Philipp and Wirtz, Ralph and Bolenz, Christian and Roghmann, Florian and Stoehr, Robert and Bahlinger, Veronika and Hartmann, Arndt and Burger, Maximilian and Breyer, Johannes and Eckstein, Markus (2025) Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer. EUROPEAN UROLOGY OPEN SCIENCE, 77. pp. 1-9. ISSN 2666-1691, 2666-1683

Full text not available from this repository. (Request a copy)

Abstract

Background and objective: Our aim was to provide a comprehensive analysis of the prevalence of potentially targetable activating FGFR3 alterations and their impact on oncological outcomes across different urothelial carcinoma (UC) stages. Methods: We retrospectively analyzed clinical data and FGFR3 results for 1509 formalin-fixed, paraffin-embedded tissue specimens. Actionable activating FGFR3 mutations were assessed using a well-established multiplex SNaPshot polymerase chain reaction approach. FGFR3 fusion testing was performed with a Qiagen Therascreen kit. Key findings and limitations: In the study population of 1509 patients, 202 (13%) had stage pTa, 380 (25%) had stage pT1, 258 (17%) had localized muscle-invasive bladder cancer (MIBC), 556 (37%) had locally advanced MIBC, 91 (6.0%) had metastatic UC of the bladder (mUCB), and 22 (1.5%) had metastatic upper tract UC (mUTUC). Of the FGFR3 alterations detected in 373 patients (25%), 104 (52%) were in stage pTa, 158 (42%) were in pT1, 42 (16%) were in localized MIBC, 53 (9.5%) were in locally advanced MIBC, nine (9.9%) were in mUCB, and seven (32%) were in mUTUC. FGFR3 alterations were associated with better progression-free survival and overall survival in the overall population (p < 0.001), but not in subgroup analyses for different disease stages. Study limitations include the retrospective design and heterogeneous patient cohort.

Item Type: Article
Uncontrolled Keywords: FACTOR RECEPTOR-3 MUTATIONS; BLADDER-CANCER; EXPRESSION; FGFR3 alteration; Targeted therapy; Urothelial carcinoma; Proliferation; Tumor growth
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Urologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 18 Nov 2026 06:29
Last Modified: 18 Nov 2026 06:29
URI: https://pred.uni-regensburg.de/id/eprint/67231

Actions (login required)

View Item View Item